Global Cardiac Assist Devices Market - Industry Analysis and Forecasts 2016-2021

Report Code: HC-R-17-38 | Page Numbers: 73

Globally, there are around 25 million cases of Heart failure. The scarcity of donor organs to meet the demands has steered to the development of Cardiac Assist Devices. These are sort of mechanical pumps that work laterally with the heart to enhance its pumping efficiency and uphold the optimum blood flow throughout the body. These devices are employed in patients suffering from End-Stage Congestive Heart Failure, where the chances of survival through medications alone is minimal. Various pipeline products are going through clinical trials in order to provide vigorous clinical data on the safety and efficacy of the devices. The launch and approval of novel technologically advanced products will further increase the demand for cardiac assist devices in the future.

Rise in global aging population, upsurge in occurrence of cardiovascular diseases, technological advancements and availability of more efficient and minimally invasive devices in future are driving the global cardiac assist devices market. Furthermore, lack of donor hearts for transplantation is also driving the cardiac assist devices implantations in patients with severe heart complications, thereby increasing the market opportunities.

Existence of alternative treatment like pacemaker, heart tr...

Buy Now

"Get Notified On all out New and Upcoming Reports"

       on all the latest research reports

Globally, there are around 25 million cases of Heart failure. The scarcity of donor organs to meet the demands has steered to the development of Cardiac Assist Devices. These are sort of mechanical pumps that work laterally with the heart to enhance its pumping efficiency and uphold the optimum blood flow throughout the body. These devices are employed in patients suffering from End-Stage Congestive Heart Failure, where the chances of survival through medications alone is minimal. Various pipeline products are going through clinical trials in order to provide vigorous clinical data on the safety and efficacy of the devices. The launch and approval of novel technologically advanced products will further increase the demand for cardiac assist devices in the future.

Rise in global aging population, upsurge in occurrence of cardiovascular diseases, technological advancements and availability of more efficient and minimally invasive devices in future are driving the global cardiac assist devices market. Furthermore, lack of donor hearts for transplantation is also driving the cardiac assist devices implantations in patients with severe heart complications, thereby increasing the market opportunities.

Existence of alternative treatment like pacemaker, heart transplantation and etc. and the risks associated with the device implantation, such as respiratory failure, development of blood clots and device failure restrain the market growth. Adding to these, surgical impediments such as kidney failure, bleeding, Infection and occurrence of stroke are also acting as a barrier in the adoption of such devices.

The global cardiac assist devices market is segmented on the basis of type into GLOBAL CARDIAC ASSIST DEVICES MARKET, BY PRODUCT TYPE (TOTAL ARTIFICIAL HEART (GLOBAL TOTAL ARTIFICIAL HEART MARKET, GLOBAL VENTRICULAR ASSIST DEVICE MARKET), In addition, on the basis of geography the market is analysed under various regions namely, North America, Europe, Latin America, Asia- Pacific, Middle-east & Africa. North America accounts for the major share in the Global cardiac assist devices, with highest prevalent cases with heart failure. And high patient awareness, technological development, and reimbursements for cardiac assist devices implantation procedures are also helping the market growth in this region. It is followed by Europe, with the second largest market.


Thoratec Corporation is the leading provider of VADs, which controls half of the European Market and major share of the US market. Some other major players on the market include Abiomed, Inc. Berlin Heart, GmbH, HeartWare International, Jarvik Heart, Inc. and Terumo Corporation.
This report provides the Cardiac Assist Devices Market Forecasting Model, offers valuable insights on global evolution, regional variation, and current market trends. The report also provides Company Profiles with Pipeline Products and financials. Most of the products are being developed collaboratively between pharmaceutical and diagnostics companies.
1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY
2 CARDIAC ASSIST DEVICES MARKET OVERVIEW
2.1 GLOBAL CARDIAC ASSIST DEVICES INTRODUCTION
2.1.1 CONTEXT AND BACKGROUND
2.1.2 CARDIOVASCULAR DISEASES, TREATMENT AND MANAGEMENT
2.1.3 CARDIAC ASSIST DEVICE TYPES
2.1.4.1 EUROPE REGULATION
2.1.4.2 UNITED STATES REGULATION
3 GLOBAL CARDIAC ASSIST DEVICES - MARKET FORCES
3.1 MARKET DRIVERS
3.1.1 ADVANCEMENTS IN TECHNOLOGY
3.1.2 INCREASE IN AGING POPULATION
3.1.3 INCREASING CARDIOVASCULAR DISEASE PREVALENCE:
3.2 MARKET RESTRAINTS
3.2.1 EXPENSIVE INSTRUMENTS & MAINTENANCE
4. GLOBAL CARDIAC ASSIST DEVICES MARKET, BY PRODUCT TYPE
4.1 TOTAL ARTIFICIAL HEART
4.1.1 GLOBAL TOTAL ARTIFICIAL HEART MARKET
4.1.2 GLOBAL VENTRICULAR ASSIST DEVICE MARKET
4.2 CARDIAC ASSIST DEVICE MARKET SHARE ANALYSIS
4.2.1 VENTRICULAR ASSIST DEVICE MARKET SHARE ANALYSIS
5. ACQUISITION ANALYSIS:
5.1. ST. JUDE MEDICAL -THORATEC ACQUISITION ANALYSIS
5.1.1 EXPANDS PRODUCT PORTFOLIO AND PIPELINE PRODUCT OWNERSHIP:
5.1.2 PRODUCT PIPELINE OWNERSHIP
5.1.3 EXPANDS LEADERSHIP POSITION IN HEART FAILURE MARKET
5.1.4 EXPANSION IN SALES MIX
5.1.5 EXPANSION IN GEOGRAPHICAL SALES MIX
5.2. HEARTWARE'S ACQUISITION OF VALTECHCARDIO ACQUISITION
5.2.1 ADDITION OF EXTENSIVE RANGE OF SURGICAL AND TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR AND REPLACEMENT TECHNOLOGIES TO PRODUCT PORTFOLIO
5.2.2 HEARTWARE + VALTECH CARDIO PRODUCTS
5.2.3 EXPANSION IN POSITION AS A LEADER IN THE TREATMENT OF HEART FAILURE PATIENTS
5.2.4 PIPELINE PRODUCTS OWNERSHIP
5.2.5 CLINICAL TRIALS AND COMMERCIALIZATION STATUS:
6 COMPETITIVE LANDSCAPE
6.1 ABIOMED
6.1.1 PARTNERSHIP, COLLABORATION AND AGREEMENT
6.1.2 MERGERS AND ACQUISITIONS
6.1.3 NEW PRODUCT LAUNCH
6.2 BIVACOR
6.2.1 NEW PRODUCT LAUNCHES
6.3 CALON CARDIO
6.3.1 NEW PRODUCT LAUNCHES
6.4 CARDIAC ASSIST,INC.
6.4.1 NEW PRODUCT LAUNCHES
6.5 CARDIO KINETIX
6.5.1 AGREEMENTS, COLLABORATION AND PARTNERSHIP
6.6 HEARTWARE
6.6.1 PARTNERSHIP
6.7 RELIANT HEART
6.7.1 COLLABORATION, PARTNERSHIP AND AGREEMENT
6.8 THORATEC CORPORATION
6.8.1 MERGERS AND ACQUISITIONS
7 COMPANY PROFILES
7.1 ABIOMED
7.1.1 OVERVIEW:
7.1.2 PRODUCTS & SERVICES:
7.1.3 FINANCIALS
7.1.4 BUSINESS STRATEGY
7.1.5 ANALYST VIEW:
7.2 BIVACOR
7.2.1 OVERVIEW:
7.2.2 PRODUCTS & SERVICES:
7.2.3 ANALYST VIEW:
7.3 CALON CARDIO
7.3.1 OVERVIEW:
7.3.2 PRODUCTS & SERVICES:
7.3.3 ANALYST VIEW:
7.4 CARDIACASSIST
7.4.1 OVERVIEW
7.4.2 PRODUCTS
7.4.3 ANALYST VIEW
7.5 CARDIOBRIDGE GMBH
7.5.1 OVERVIEW:
7.5.2 PRODUCTS & SERVICES
7.5.3 ANALYST VIEW:
7.6 CARDIOKINETIX, INC.,
7.6.1 OVERVIEW
7.6.2 PRODUCTS & SERVICES:
7.6.3 ANALYST VIEW
7.7 CARMAT
7.7.1 OVERVIEW
7.7.2 PIPELINE PRODUCTS
7.7.3
7.8 CORASSIST CARDIOVASCULAR LTD
7.8.1 OVERVIEW
7.8.2 PIPELINE PRODUCTS
7.9 EVAHEART
7.9.1 OVERVIEW:
7.9.2 PIPELINE PRODUCTS:
7.10 HEARTWARE
7.10.1 OVERVIEW:
7.10.2 MAJOR PRODUCTS:
7.10.3 PIPELINE PRODUCTS:
7.10.4 BUSINESS STRATEGY
7.10.5 FINANCIALS
7.10.6 ANALYST VIEW:
7.11 JARVIK HEART, INC
7.11.1 OVERVIEW
7.11.2 PIPELINE PRODUCTS
7.11.3 RECENT DEVELOPMENTS:
7.12 LEVITICUS CARDIO
7.12.1 OVERVIEW
7.12.2 PIPELINE PRODUCTS
7.13 LONESTAR HEART, INC
7.13.1 OVERVIEW
7.13.2 PIPELINE PRODUCTS
7.14 RELIANT HEART
7.14.1 OVERVIEW
7.14.2 PIPELINE PRODUCTS
7.14.3 ANALYST VIEW
7.15 MYOCARDIOCARE
7.15.1 OVERVIEW
7.15.2 PIPELINE PRODUCTS
7.15.3 ANALYST VIEW
7.16 NEOCARDIAL TECHNOLOGIES
7.16.1 OVERVIEW
7.16.2 PIPELINE PRODUCTS
7.16.3 ANALYST VIEW
7.17 PROCYRION, INC.
7.17.1 OVERVIEW
7.17.2 PIPELINE PRODUCTS
7.18 SUNSHINE HEART, INC.,
7.18.1 OVERVIEW:
7.18.2 MAJOR PRODUCTS:
7.18.3 BUSINESS STRATEGY:
7.18.4 FINANCIALS:
7.18.5 ANALYST VIEW:
7.19 SYNCARDIA SYSTEMS, INC
7.19.1 OVERVIEW:
7.19.2 MAJOR PRODUCT:
7.19.3 PIPELINE PRODUCTS:
7.19.4 ANALYST VIEW:
7.20 TERUMO CORPORATION
7.20.1 OVERVIEW:
7.20.2 MAJOR PRODUCTS:
7.20.3 FINANCIALS:
7.21 THORATEC CORPORATION
7.21.1 OVERVIEW
7.21.2 MAJOR PRODUCTS
7.21.3 PIPELINE PRODUCTS
7.21.4 BUSINESS STRATEGY
7.21.5 FINANCIALS:
Globally, there are around 25 million cases of Heart failure. The scarcity of donor organs to meet the demands has steered to the development of Cardiac Assist Devices. These are sort of mechanical pumps that work laterally with the heart to enhance its pumping efficiency and uphold the optimum blood flow throughout the body. These devices are employed in patients suffering from End-Stage Congestive Heart Failure, where the chances of survival through medications alone is minimal. Various pipeline products are going through clinical trials in order to provide vigorous clinical data on the safety and efficacy of the devices. The launch and approval of novel technologically advanced products will further increase the demand for cardiac assist devices in the future.

Rise in global aging population, upsurge in occurrence of cardiovascular diseases, technological advancements and availability of more efficient and minimally invasive devices in future are driving the global cardiac assist devices market. Furthermore, lack of donor hearts for transplantation is also driving the cardiac assist devices implantations in patients with severe heart complications, thereby increasing the market opportunities.

Existence of alternative treatment like pacemaker, heart transplantation and etc. and the risks associated with the device implantation, such as respiratory failure, development of blood clots and device failure restrain the market growth. Adding to these, surgical impediments such as kidney failure, bleeding, Infection and occurrence of stroke are also acting as a barrier in the adoption of such devices.

The global cardiac assist devices market is segmented on the basis of type into GLOBAL CARDIAC ASSIST DEVICES MARKET, BY PRODUCT TYPE (TOTAL ARTIFICIAL HEART (GLOBAL TOTAL ARTIFICIAL HEART MARKET, GLOBAL VENTRICULAR ASSIST DEVICE MARKET), In addition, on the basis of geography the market is analysed under various regions namely, North America, Europe, Latin America, Asia- Pacific, Middle-east & Africa. North America accounts for the major share in the Global cardiac assist devices, with highest prevalent cases with heart failure. And high patient awareness, technological development, and reimbursements for cardiac assist devices implantation procedures are also helping the market growth in this region. It is followed by Europe, with the second largest market.


Thoratec Corporation is the leading provider of VADs, which controls half of the European Market and major share of the US market. Some other major players on the market include Abiomed, Inc. Berlin Heart, GmbH, HeartWare International, Jarvik Heart, Inc. and Terumo Corporation.
This report provides the Cardiac Assist Devices Market Forecasting Model, offers valuable insights on global evolution, regional variation, and current market trends. The report also provides Company Profiles with Pipeline Products and financials. Most of the products are being developed collaboratively between pharmaceutical and diagnostics companies.

Download Sample

Just fill the short form below to get the sample

Don’t like forms? Give us a call. U.S. +1(973)805-7440 (International) Email us at: amit@ceskaa.com